OMEICOS Therapeutics raises sights with extension into ophthalmics

Berlin’s OMEICOS Therapeutics has extended its series B financing round and established a US subsidiary, OMEICOS Ophthalmics, in Massachusetts.

The firm raised 8.3 million euros ($9.8 million) earlier in the year from mainly German investors to fund a Phase I trial with lead compound OMT-28 in atrial fibrillation.

The financing extension, led by US-based REMIGES Ventures, is aimed at expanding into ophthalmological disorders.

The company’s technology is based on stable synthetic small molecules which mimic aspects of omega-3 fatty acids.

OMEICOS aims to initiate pre-clinical work on a range of compounds and different routes of administration for different types of eye diseases, like age-related macular degeneration.

The company was span out of the Max Delbrueck Center for Molecular Medicine.